EyeGene is a KOSDAQ listed clinical stage biotechnology company based in Korea involved in the research and development of innovative bio-pharmaceutical products.
1) mRNA SARS-COV-2 vaccine is currently being developed with cationic liposome delivery technology.
2) Herpes zoster vaccine is being used to develop a wide range of premium prophylactic vaccines as using own novel immune adjuvant technology(Herpes zoster, HPV etc.).
3) Treatments for ischemic diseases are currently being developed with advanced recombinant protein technology.
4) mRNA personalized cancer vaccines are being developed.
Development status of our lead candidates:
1) EG-COVID(mRNA SARS-COV-2 vaccine, Phase 1/2a in Korea, Australia and South Africa).
2) EG-HZ(Herpes Zoster Vaccine, Phase I in Australia complete), EG-HPV (HPV Vaccine, Korea, Phase I complete)
3) EG-Mirotin (DME with Diabetic Retinopathy, EU and Korea, Phase IIa), EG-Decorin (Pressure Ulcer/Bedsore, Korea, Phase I/II and Wound healing, Korea, Phase II), EG-Myocin(Myocardial Ischemia/Reperfusion Injury, Korea, Phase II)
EG-COVID(mRNA SARS-COV-2 vaccine, using own novel immune adjuvant technology) currently is undergoing Phase 1/2a clinical trial in Korea and Australia. We are also looking for licensing partners for global territorial rights for this pipeline.
EG-HZ Vaccine consists of VZV glycoprotein E + CIA09A. CIA09A is one of our proprietary adjuvant systems. It will stimulate suitable immune system for people who have weakened immunity. It is completed Phase I clinical trial in Australia(2021).
EG-Mirotin (therapeutic agent for Diabetic Retinopathy) completed Phase 2a trials in EU and Korea . We are looking for licensing partners for global territorial rights.
EG-Decorin’s domestic territorial rights have been licensed out to Huons respectively (leading pharmaceutical companies in Korea). We are actively looking for licensing partners for global regions ex-Korea.
EG-Myocin (therapeutic agent for Myocardial Ischemia/Reperfusion Injury) currently is undergoing Phase II clinical trial in Korea. We are also looking for licensing partners for global territorial rights for this pipeline.
EG-HPV consists of Virus Like Particles (VLPs) + CIA06 (immune adjuvant). It is completed Phase I clinical trial in Korea.
1) mRNA SARS-COV-2 vaccine is currently being developed with cationic liposome delivery technology.
2) Herpes zoster vaccine is being used to develop a wide range of premium prophylactic vaccines as using own novel immune adjuvant technology(Herpes zoster, HPV etc.).
3) Treatments for ischemic diseases are currently being developed with advanced recombinant protein technology.
4) mRNA personalized cancer vaccines are being developed.
Development status of our lead candidates:
1) EG-COVID(mRNA SARS-COV-2 vaccine, Phase 1/2a in Korea, Australia and South Africa).
2) EG-HZ(Herpes Zoster Vaccine, Phase I in Australia complete), EG-HPV (HPV Vaccine, Korea, Phase I complete)
3) EG-Mirotin (DME with Diabetic Retinopathy, EU and Korea, Phase IIa), EG-Decorin (Pressure Ulcer/Bedsore, Korea, Phase I/II and Wound healing, Korea, Phase II), EG-Myocin(Myocardial Ischemia/Reperfusion Injury, Korea, Phase II)
EG-COVID(mRNA SARS-COV-2 vaccine, using own novel immune adjuvant technology) currently is undergoing Phase 1/2a clinical trial in Korea and Australia. We are also looking for licensing partners for global territorial rights for this pipeline.
EG-HZ Vaccine consists of VZV glycoprotein E + CIA09A. CIA09A is one of our proprietary adjuvant systems. It will stimulate suitable immune system for people who have weakened immunity. It is completed Phase I clinical trial in Australia(2021).
EG-Mirotin (therapeutic agent for Diabetic Retinopathy) completed Phase 2a trials in EU and Korea . We are looking for licensing partners for global territorial rights.
EG-Decorin’s domestic territorial rights have been licensed out to Huons respectively (leading pharmaceutical companies in Korea). We are actively looking for licensing partners for global regions ex-Korea.
EG-Myocin (therapeutic agent for Myocardial Ischemia/Reperfusion Injury) currently is undergoing Phase II clinical trial in Korea. We are also looking for licensing partners for global territorial rights for this pipeline.
EG-HPV consists of Virus Like Particles (VLPs) + CIA06 (immune adjuvant). It is completed Phase I clinical trial in Korea.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
